stockportfolio.pro
Evommune, Inc. (EVMN)
Healthcare · Biotechnology · NYSE
Evommune, Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $7.00M | $13.00M |
| Gross profit | — | — |
| Net income | $-66.81M | $-68.87M |
| Net margin | -954.4% | -529.8% |
Source: Evommune, Inc. SEC filings (10-K).
Explore 2 years of Evommune, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track EVMN in your portfolio →
Evommune, Inc. financial history by metric
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Evommune, Inc. — frequently asked questions
What is Evommune, Inc.'s revenue?
Evommune, Inc. (EVMN) reported revenue of $13.00M for fiscal year 2025, up 85.7% from the prior year, according to its SEC filings.
Is Evommune, Inc. profitable?
No — EVMN reported a net loss of $-68.87M in fiscal 2025.
What is EVMN's P/E ratio?
Evommune, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Evommune, Inc. have?
As of fiscal year 2025, EVMN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Evommune, Inc.'s market cap?
Evommune, Inc. (EVMN) has a market capitalization of about $746.30M, based on the latest data in our nightly-refreshed cache.
When does Evommune, Inc.'s fiscal year end?
EVMN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Evommune, Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.